These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 24013526)
41. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504 [TBL] [Abstract][Full Text] [Related]
42. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Iwamoto S; Hazama S; Kato T; Miyake Y; Fukunaga M; Matsuda C; Bando H; Sakamoto J; Oba K; Mishima H Anticancer Res; 2014 Apr; 34(4):1967-73. PubMed ID: 24692733 [TBL] [Abstract][Full Text] [Related]
43. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544 [TBL] [Abstract][Full Text] [Related]
44. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. Chung KY; Shia J; Kemeny NE; Shah M; Schwartz GK; Tse A; Hamilton A; Pan D; Schrag D; Schwartz L; Klimstra DS; Fridman D; Kelsen DP; Saltz LB J Clin Oncol; 2005 Mar; 23(9):1803-10. PubMed ID: 15677699 [TBL] [Abstract][Full Text] [Related]
45. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810 [TBL] [Abstract][Full Text] [Related]
46. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Stintzing S; Kapaun C; Laubender RP; Jung A; Neumann J; Modest DP; Giessen C; Moosmann N; Wollenberg A; Kirchner T; Heinemann V Int J Cancer; 2013 Jan; 132(1):236-45. PubMed ID: 22644776 [TBL] [Abstract][Full Text] [Related]
47. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388 [TBL] [Abstract][Full Text] [Related]
48. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213 [TBL] [Abstract][Full Text] [Related]
49. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens. Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808 [TBL] [Abstract][Full Text] [Related]
50. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. Personeni N; Hendlisz A; Gallez J; Galdon MG; Larsimont D; Van Laethem JL; Nagy N; Barette M; Paesmans M; Cardoso F; Bleiberg H Semin Oncol; 2005 Dec; 32(6 Suppl 9):S59-62. PubMed ID: 16399434 [TBL] [Abstract][Full Text] [Related]
51. A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer. Ishiguro M; Watanabe T; Yamaguchi K; Satoh T; Ito H; Seriu T; Sakata Y; Sugihara K Jpn J Clin Oncol; 2012 Apr; 42(4):287-94. PubMed ID: 22327124 [TBL] [Abstract][Full Text] [Related]
52. Cetuximab-induced skin reactions are suppressed by cigarette smoking in patients with advanced colorectal cancer. Kajizono M; Saito M; Maeda M; Yamaji K; Fujiwara S; Kawasaki Y; Matsunaga H; Sendo T Int J Clin Oncol; 2013 Aug; 18(4):684-8. PubMed ID: 22678464 [TBL] [Abstract][Full Text] [Related]
54. The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients. Tang XM; Chen H; Liu Y; Huang BL; Zhang XQ; Yuan JM; He X Medicine (Baltimore); 2017 Jan; 96(3):e5946. PubMed ID: 28099361 [TBL] [Abstract][Full Text] [Related]
55. Effect of risk factors for acneiform rash induced by anti-epidermal growth factor receptor antibody drugs on survival: a retrospective observational study. Takahashi H; Yaegashi Y; Saito Y; Nihei S; Tairabune T; Ujiie H; Asaka J; Kudo K J Pharm Health Care Sci; 2022 Sep; 8(1):22. PubMed ID: 36045384 [TBL] [Abstract][Full Text] [Related]
56. Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in animal cancer models. Wang Q; Gavin W; Masiello N; Tran KB; Laible G; Shepherd PR Biotechnol Rep (Amst); 2020 Dec; 28():e00533. PubMed ID: 33024714 [TBL] [Abstract][Full Text] [Related]
57. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C Oncology; 2014; 87(1):7-20. PubMed ID: 24968756 [TBL] [Abstract][Full Text] [Related]
58. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? Maughan TS; Meade AM; Adams RA; Richman SD; Butler R; Fisher D; Wilson RH; Jasani B; Taylor GR; Williams GT; Sampson JR; Seymour MT; Nichols LL; Kenny SL; Nelson A; Sampson CM; Hodgkinson E; Bridgewater JA; Furniss DL; Roy R; Pope MJ; Pope JK; Parmar M; Quirke P; Kaplan R Br J Cancer; 2014 Apr; 110(9):2178-86. PubMed ID: 24743706 [TBL] [Abstract][Full Text] [Related]
59. A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer. Mizushima T; Ide Y; Murata K; Ohashi I; Yasumasa K; Fukunaga M; Takemoto H; Tamagawa H; Hasegawa J; Hata T; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M Oncology; 2013; 85(6):317-22. PubMed ID: 24247419 [TBL] [Abstract][Full Text] [Related]
60. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]